Lexicon Pharmaceuticals (LXRX) Asset Writedowns and Impairment (2010 - 2020)
Lexicon Pharmaceuticals' (LXRX) quarterly Asset Writedowns and Impairment came in at $1.6 million in Q2 2020, up 105.59% on a QoQ basis from -$28.6 million in Q4 2019.
Lexicon Pharmaceuticals (LXRX) Asset Writedowns and Impairment (2010 - 2020) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 6 years of Asset Writedowns and Impairment data on file, last reported at $1.6 million in Q2 2020.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to $1.6 million in Q2 2020; TTM through Sep 2021 was $1.6 million, a 0.0% change from a year earlier, with the FY2020 full-year figure at $1.6 million, changed N/A from the prior year.
- Asset Writedowns and Impairment for Q2 2020 stood at $1.6 million, up from -$28.6 million in the prior quarter.
- Over the last five years, Asset Writedowns and Impairment for LXRX reached as high as $28.6 million in Q3 2019 and fell as low as -$28.6 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,719.23 Bn | 65,718.94 Bn | - |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 471.85 Bn | 467.06 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.29 Bn | 115.04 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.28 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Lexicon Pharmaceuticals | 918.55 Mn | 747.89 Mn | 20.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 1.60 Mn |
| Jun 30, 2020 | 1.60 Mn |
| Dec 31, 2019 | -28.64 Mn |
| Dec 31, 2019 | -28.64 Mn |
| Sep 30, 2019 | 28.64 Mn |
| Sep 30, 2019 | 28.64 Mn |
| Dec 31, 2015 | 1.25 Mn |
| Dec 31, 2015 | 1.25 Mn |
| Sep 30, 2015 | 2.35 Mn |
| Sep 30, 2015 | 2.35 Mn |
| Dec 31, 2014 | 200,000.00 |
| Dec 31, 2014 | 200,000.00 |
| Sep 30, 2014 | 13.10 Mn |
| Sep 30, 2014 | 13.10 Mn |
| Mar 31, 2014 | 242,000.00 |
| Mar 31, 2014 | 242,000.00 |
| Dec 31, 2011 | -2,000.00 |
| Dec 31, 2011 | -2,000.00 |
| Sep 30, 2011 | -79,000.00 |
| Sep 30, 2011 | -79,000.00 |